FDA Warning on Xylazine: Mitigating Human Risk | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...
DEA Limits Quotas Key Reductions, 2019 versus 2018 per HDA: ANPP 88% Codeine (for conversion) 90% Dihydrocodeine 90% Dihydromorphine* 74% Fentanyl...
DEA Makes Moves 2018 Series, Part 1: Pharmacies & Red Flags In recent months, the DEA has begun ramping up its enforcement efforts across the...
4th Largest US Wholesaler has DEA Registration Suspended In an attempt to rein in the Opioid Epidemic, it seems that recently, the DEA has become...
DEA Offers a Tiny Peak Behind the ARCOS Curtain DEA has “enhanced” its ARCOS online reporting system to help distributors and manufacturers know...
DEA Reportedly Set to Revise SORS Guidelines and (Hopefully) Clarify the Meaning of “Suspicious” As the opioid crisis continues to grow and further...
Biggest Industry Players Face Pressure from Public and the DEA on Suspicious Order Monitoring The Opioid Epidemic has been a devastating trend in...
